Abstract
ABSTRACTCRISPR/Cas9 enables the generation of knockout cell lines and null zygotes by inducing site-specific double-stranded breaks. In most cases the DSB is repaired by non-homologous end joining, resulting in small nucleotide insertions or deletions that can be used to construct knockout alleles. However, these mutations do not produce the desired null result in all cases, but instead generate a similar, functionally active protein. This effect could limit the therapeutic efficiency of gene therapy strategies based on abrogating oncogene expression, and therefore needs to be considered carefully. If there is an acceptable degree of efficiency of CRISPR/Cas9 delivery to cells, the key step for success lies in the effectiveness of a specific sgRNA at knocking out the oncogene, when only one sgRNA can be used. This study shows that the null effect could be increased with an sgRNA targeting the splice donor site (SDS) of the chosen exon. Following this strategy, the generation of null alleles would be facilitated in two independent ways: the probability of producing a frameshift mutation and the probability of interrupting the canonical mechanism of pre-mRNA splicing. In these contexts, we propose to improve the loss-of-function yield driving the CRISPR system at the SDS of critical exons.
Publisher
Cold Spring Harbor Laboratory
Reference27 articles.
1. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
2. Grimm, D. and Kay, M.A. (2007) RNAi and gene therapy: a mutual attraction. Hematol. Am Soc Hematol Educ Progr., 10.1182/asheducation-2007.1.473.
3. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
4. Genome Editing: A New Approach to Human Therapeutics
5. Garcia-Tunon, I. , Hernandez-Sanchez, M. , Ordonez, J.L. , Alonso-Perez, V. , Alamo-Quijada, M. , Benito, R. , Guerrero, C. , Hernandez-Rivas, J.M. and Sanchez-Martin, M. (2017) The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget, 10.18632/oncotarget.15215.